Cromos Pharma celebrates Breast Cancer Awareness Month
Breast cancer is the most commonly occurring cancer in women and the second only to lung cancer as the most common cancer overall. The developed nations in North America and Western Europe lead the world in incidence (well over 60 and up to 95 per 100,000 women ages 0-69). And yet, while mortality rates in these regions have shrunk to less than 15%, in certain less developed nations in Eastern Europe, Asia, Africa, and South America, even with significantly lower incidence rates (as low as 15-20 patients per 100,000), the mortality rates remain as high as 50% or more, and represent 58% of global mortality. How can we correct this imbalance?
At Cromos Pharma, our first clinical research project was conducted in breast cancer, in only one country in Eastern Europe. Since that modest beginning, Cromos and its team have participated in dozens of studies in breast cancer patients throughout the world; the preponderance of our patients was enrolled in less developed nations. Our studies have ranged from innovative treatments to cost-advantaged generic and biosimilar therapies, from treatments for only certain types (there are many types of breast cancers, and several methods of predicting response rates to targeted therapies, based upon hormone biomarkers) to studies encompassing all patients diagnosed with breast cancer. We have studied companion therapies that enable breast cancer patients to withstand the rigors of traditional radiation and chemotherapy, and newer, gentler formulations enabling patients to tolerate higher doses for a longer treatment duration.
What do Cromos Pharma’s breast cancer research projects have in common? They have been aimed at introducing treatment modalities from developed nations to thousands of patients who live in the less developed regions of the world. They have been designed to introduce new medicines as well as less expensive but proven follow-on generic and biosimilar medications to regions where healthcare reimbursement is not available for novel or costly therapies. They have enabled physicians to provide education, early diagnosis, and advanced, targeted therapies to their patients. They have enabled many women in less developed nations to be cured, or to live with, rather than die from this disease. They have been aimed at correcting the imbalance.
Correcting the imbalance
Cromos Pharma Breast Cancer Patient Recruitment Goal for 2019:
More than one thousand patients, in one year!
Sources: Breast Health Global Initiative at Fred Hutchinson Cancer Research Center; ABC Global Alliance, American Cancer Society, World Health Organization (WHO), Cromos Pharma analysis of internal project files, non-confidential summary.
JP Morgan Healthcare Conference: Virtual Booth and Daily Presentations
Watch: The benefits of Cromos Pharma and Avance Clinical's biotech initiative
In October we launched an exciting collaboration with Avance Clinical to offer biotechs a scalable clinical trials solution. The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies. In this new video you can learn more about the benefits of this initiative.
World AIDS Day 2020: Remarkable progress but the fight continues
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
Thursday 19 November 2020 is World Pancreatic Cancer Awareness Day. Here at Cromos Pharma we are proud to play our part in supporting clinical trials aimed at finding better treatments for pancreatic cancers.
Alzheimer's Awareness Month: Q&A with Dr Sabina Brennan
September is World Alzheimer’s Month. Alzheimer’s Disease (AD) is the most well-known form of dementia. Dementia is the collective name for progressive brain conditions affecting memory, thinking, behavior and emotions. Dementia affects almost 50 million people worldwide. While aging is a major risk factor for dementia, it also affects people under 65 years. To mark Alzheimer’s Awareness Month (Sept 2020) we sat down with leading psychologist, neuroscientist and best-selling author Dr Sabina Brennan. Dr Brennan is a brain health expert who has advised Irish and UK governments on policies relating to aging and dementia. She is the Irish national representative on the Medical and Scientific Advisory Panel for Alzheimer’s Disease International.
EU cancer estimates for 2020 reveal 2.7 million new cases
The European Joint Research Council released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed.
Risk Based Monitoring- a data-centric approach to monitoring
In this Insights@CromosPharma article our Chief Operating Officer Stephanie Finnegan explores the role of Risk Based Monitoring (RBM) in clinical trials, how it has been utilized in response to the current coronavirus pandemic, and how the experience may shape the industry's approach to RBM in the future.
Cromos Pharma celebrates International Clinical Trials Day 2020
Today (20 May, 2020) marks International Clinical Trials Day 2020. Cromos Pharma wishes to express its gratitude to everyone who participates in and conducts clinical trials that help turn research into reality and make lifesaving and life-changing medical treatments available to patients all over the world.
First patients enrolled in Cromos Pharma managed Covid-19 trial
Cromos Pharma is proud to be part of the global search for effective COVID-19 treatments. Today (24 April, 2020) we are pleased to announce the enrollment of the first patients in clinical trials designed to be find drugs to treat the symptoms of coronavirus.
Master protocols are disrupting the clinical trial space by offering a more comprehensive and adaptive approach to studying treatments for the most complex of diseases. Cromos Pharma is delighted to share with you a recently published article on the topic by CEO Dr Vlad Bogin.
European Medicines Agency launches new regulatory science strategy
The European Medicines Agency (EMA) recently (31 March 2020) published its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines.
Cromos Pharma launches new series to explore the latest developments in clinical trials sector
2020 marks the start of a new decade when we can anticipate several trends to take hold in the global clinical research market. What can we expect in terms of the market in terms of growth and trends? Throughout 2020 Cromos Pharma’s team of experts will look at some of the major trends dominating the current market and future influences on clinical research.
Cromos Pharma launches a new office in Warsaw, Poland
Cromos Pharma, an international provider of clinical trial and drug development services, today (04 MARCH 2020) announced the opening of its new office in Warsaw, Poland. The opening of the new office strengthens Cromos Pharma’s position in Poland where it has been operational since 2015.
“The establishment of the Poland office is a major development in line with Cromos Pharma’s continued expansion in European and US operations marking another milestone in the sustained growth of the Company. Poland is a significant clinical trials market that has many advantages making it highly attractive to international sponsors,” said Dr. Vlad Bogin, CEO, Cromos Pharma, “Cromos Pharma looks forward to offering sponsors an extended range of our expert services through its new office to ensure effective and cost-efficient execution of clinical trials”.
With its 40 million people Poland is one of the largest clinical trials markets in Eastern Europe that has a strong track record of over 20 years in delivering high-quality research. It boasts several advantages including a large naïve population and well-developed research infrastructure. Polish patients are positively disposed to taking part in clinical trials as it offers them an opportunity to access innovative treatments otherwise not always available to them. The country has a large network of highly skilled and motivated clinical investigators and medical professionals keen to participate in clinical research. Poland also offers relatively low costs and excellent patient recruitment.
With excellent rates of patient recruitment, high-quality data, highly skilled and committed investigators, and comparatively low costs, Poland is an attractive location for sponsors. Cromos Pharma is ready to help you access these advantages through our excellent knowledge of the regulatory processes and our existing relationships with sites and investigators.
To explore these advantages and the services Cromos Pharma can offer you please email email@example.com.
About Cromos Pharma
Cromos Pharma is an international Contract Research Organization (CRO) providing tailored and effective clinical trials management to support the development of drugs that transform healthcare. It offers fully integrated services with expertise in all aspects of clinical trials of all phases in a wide range of therapeutic indications. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has an extensive network of offices across 15 countries and strong regional experience in Central and Eastern Europe. Its European HQ is situated in Dublin, Ireland and its US base is in Portland, Oregon with an operational base in South Florida.